These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 34916733)

  • 1. Potential therapeutic effect of glucagon-like peptide-1 receptor agonists on COVID-19-induced pulmonary arterial hypertension.
    Lee JH
    Med Hypotheses; 2022 Jan; 158():110739. PubMed ID: 34916733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glucagon-like peptide-1 receptor agonists in the era of COVID-19: Friend or foe?
    Belančić A; Kresović A; Troskot Dijan M
    Clin Obes; 2021 Apr; 11(2):e12439. PubMed ID: 33423388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-inflammatory effects of GLP-1 in patients with COVID-19.
    Sazgarnejad S; Yazdanpanah N; Rezaei N
    Expert Rev Anti Infect Ther; 2022 Mar; 20(3):373-381. PubMed ID: 34348067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GLP-1 receptor agonists in the treatment of type 2 diabetes: role and clinical experience to date.
    Brunton SA; Wysham CH
    Postgrad Med; 2020 Nov; 132(sup2):3-14. PubMed ID: 32815454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment Strategy for Type 2 Diabetes with Obesity: Focus on Glucagon-like Peptide-1 Receptor Agonists.
    Ji Q
    Clin Ther; 2017 Jun; 39(6):1244-1264. PubMed ID: 28526416
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How Do SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors and GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists Reduce Cardiovascular Outcomes?: Completed and Ongoing Mechanistic Trials.
    Lee MMY; Petrie MC; McMurray JJV; Sattar N
    Arterioscler Thromb Vasc Biol; 2020 Mar; 40(3):506-522. PubMed ID: 31996025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glucagon-like Peptide-1 Receptor Agonists: A Class Update for Treating Type 2 Diabetes.
    Lovshin JA
    Can J Diabetes; 2017 Oct; 41(5):524-535. PubMed ID: 28942790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glucagon-Like Peptide-1 Receptor Agonist Attenuates Autophagy to Ameliorate Pulmonary Arterial Hypertension through Drp1/NOX- and Atg-5/Atg-7/Beclin-1/LC3β Pathways.
    Wu YC; Wang WT; Lee SS; Kuo YR; Wang YC; Yen SJ; Lee MY; Yeh JL
    Int J Mol Sci; 2019 Jul; 20(14):. PubMed ID: 31336911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. COVID-19 patients may become predisposed to pulmonary arterial hypertension.
    Suzuki YJ; Nikolaienko SI; Shults NV; Gychka SG
    Med Hypotheses; 2021 Feb; 147():110483. PubMed ID: 33444904
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Review of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes mellitus in patients with chronic kidney disease and their renal effects.
    Sloan LA
    J Diabetes; 2019 Dec; 11(12):938-948. PubMed ID: 31318152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oxidative stress and inflammation in COVID-19: potential application OF GLP-1 receptor agonists.
    Abudalo RA; Alqudah AM; Roarty C; Athamneh RY; Grieve DJ
    Eur Rev Med Pharmacol Sci; 2023 Jul; 27(13):6459-6471. PubMed ID: 37458671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk factors: A narrative review of head-to-head comparisons.
    Dalsgaard NB; Vilsbøll T; Knop FK
    Diabetes Obes Metab; 2018 Mar; 20(3):508-519. PubMed ID: 29024408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Perspectives in GLP-1 Research: New Targets, New Receptors.
    Cantini G; Mannucci E; Luconi M
    Trends Endocrinol Metab; 2016 Jun; 27(6):427-438. PubMed ID: 27091492
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GLP-1 Receptor Signaling Differentially Modifies the Outcomes of Sterile vs Viral Pulmonary Inflammation in Male Mice.
    Sato T; Shimizu T; Fujita H; Imai Y; Drucker DJ; Seino Y; Yamada Y
    Endocrinology; 2020 Dec; 161(12):. PubMed ID: 33125041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The anti-inflammatory and immunological properties of GLP-1 Receptor Agonists.
    Bendotti G; Montefusco L; Lunati ME; Usuelli V; Pastore I; Lazzaroni E; Assi E; Seelam AJ; El Essawy B; Jang J; Loretelli C; D'Addio F; Berra C; Ben Nasr M; Zuccotti G; Fiorina P
    Pharmacol Res; 2022 Aug; 182():106320. PubMed ID: 35738455
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of GLP-1 Analogs in the Management of Diabetes and its Secondary Complication.
    Sivakumar PM; Premkumar B; Prabhawathi V; Prabhakar PK
    Mini Rev Med Chem; 2021; 21(20):3166-3182. PubMed ID: 33888049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Role of Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes in Asia.
    Lu JM
    Adv Ther; 2019 Apr; 36(4):798-805. PubMed ID: 30859500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Role of the Pharmacist in Managing Type 2 Diabetes with Glucagon-Like Peptide-1 Receptor Agonists as Add-On Therapy.
    Meece J
    Adv Ther; 2017 Mar; 34(3):638-657. PubMed ID: 28210986
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between glucagon-like peptide-1 receptor agonists and biliary-related diseases in patients with type 2 diabetes: A nationwide cohort study.
    Dong YH; Wu JH; Chang CH; Lin JW; Wu LC; Toh S
    Pharmacotherapy; 2022 Jun; 42(6):483-494. PubMed ID: 35508702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Benefits of GLP-1 (Glucagon-Like Peptide 1) Receptor Agonists for Stroke Reduction in Type 2 Diabetes: A Call to Action for Neurologists.
    Goldenberg RM; Cheng AYY; Fitzpatrick T; Gilbert JD; Verma S; Hopyan JJ
    Stroke; 2022 May; 53(5):1813-1822. PubMed ID: 35259929
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.